United Kingdom · Question · Written question
HL HL539
National Institute for Health and Care Excellence: Standards
Introduced
25 May 2022
Last action
7 June 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
7 June 2022
Summary
To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 17 May (HL147), how the National Institute for Health and Care Excellence (NICE) appraisals of (1) Sacituzumab govitecan (Trodelvy), and (2) Tucatinib (Tukysa) with trastuzum
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
25 May 2022
Written question
To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 17 May (HL147), how the National Institute for Health and Care Excellence (NICE) appraisals of (1) Sacituzumab govitecan (Trodelvy), and (2) Tucatinib (Tukysa) with trastuzum
Source: Lords
7 June 2022
Answer
The appraisal of sacituzumab govitecan is not included in this statistic as the National Institute for Health and Care Excellence (NICE) has not yet issued its final guidance. The appraisal of tucatinib is not recorded by the timeliness metric for 2021/22...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-05-25/HL539
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1466067
- uk · wq-1466067 · source updated 7 June 2022